Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051327 | 0.84 | LMNA (0.90) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL9876237 | 0.80 | LMNA (0.54) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| Guaiazulen SCHEMBL29259925 | 0.80 | LMNA (1.00) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| Guaiazulen SCHEMBL26982 | 0.80 | LMNA (1.00) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| Guaiazulen SCHEMBL29639620 | 0.80 | LMNA (1.00) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| Guaiazulen SCHEMBL7916824 | 0.78 | LMNA (0.95) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| Guaiazulen SCHEMBL27806695 | 0.78 | LMNA (0.95) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL8850182 | 0.78 | LMNA (0.57) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL30865662 | 0.78 | LMNA (0.47) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL9875662 | 0.76 | LMNA (0.55) | LMNAPTGS1TRPA1CACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655386-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF CARBON-CONTAINING NON-NITROGEN COMPOUNDS | Fertis India Pvt Ltd (IN) | 2025-12-03 | — | — | EP | claimed |
| US-20250248400-A1 | NANOPARTICULATE FORMULATION FOR PREVENTING OR TREATING CALLOSE FORMATION IN PLANTS | PURDUE RESEARCH FOUNDATION (US) | 2025-08-07 | — | — | US | claimed |
| WO-2024121870-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF CARBON-CONTAINING NON-NITROGEN COMPOUNDS | FERTIS INDIA PVT. LTD. (IN) | 2024-06-13 | — | — | WO | claimed |
| US-20230380428-A1 | BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS | SUSTAINABLE COMMUNITY DEV LLC (US) | 2023-11-30 | — | — | US | claimed |
| WO-2022081174-A1 | BIODEGRADABLE CLEANING PRODUCTS, METHODS OF PRODUCTION, AND THEIR COMPOSITIONS | SUSTAINABLE COMMUNITY DEVELOPMENT, LLC (US) | 2022-04-21 | — | — | WO | claimed |
| US-20190224193-A1 | Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases | REID CHRISTOPHER BRIAN (US) | 2019-07-25 | — | — | US | claimed |
| WO-2018111194-A1 | TARGETS FOR IMPROVING TERPENE PRODUCTION IN RHODOSPORIDIUM TORULOIDES | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2018-06-21 | — | — | WO | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| WO-2007066305-A1 | COMPOSITIONS COMPRISING SESQUITERPENE COMPOUNDS FOR USE IN THE PROPHYLAXIS OR TREATMENT OF PAIN | ZELPY 2549 (PTY) LIMITED (ZA) | 2007-06-14 | — | — | WO | claimed |
| US-20260041726-A1 | OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAINING | CONCEPT MATRIX SOLUTIONS (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250369022-A1 | PRODUCTION OF NATURAL GUM BASE INGREDIENTS BY PLANT CELL FERMENTATION AND APPLICATION THEREOF IN CONFECTIONERY | WM. WRIGLEY JR. COMPANY (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4655386-A1 | GENETIC MODIFICATION OF MICROBES FOR PRODUCTION OF CARBON-CONTAINING NON-NITROGEN COMPOUNDS | Fertis India Pvt Ltd (IN) | 2025-12-03 | — | — | EP | disclosed |
| WO-2005013931-A1 | USE OF HALOGENATED HYDROXYDIPHENYL ETHER COMPOUNDS FOR THE TREATMENT OF THE SKIN | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-6673756-B2 | MULTILAYER; CUTTING, JOINING UNDER PRESSURE | SYMRISE GMBH & CO. KG (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20020173436-A1 | Multilayer; cutting, joining under pressure | SYMRISE GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
| US-6069113-A | GIVEN AMOUNT OF TERPENE, AN EMULSIFIER COMPRISING THE REACTION PRODUCT OF A TALL OIL FATTY ACID AND AN ALCOHOL AMINE, AND A COPPER COMPLEX; LESS TOXIC AND LESS FLAMMABLE | LAPORTE WATER TECHNOLOGIES & BIOCHEM, INC. (US) | 2000-05-30 | — | — | US | disclosed |
| US-5112358-A | Terpene Solvents | PARADIGM TECHNOLOGY CO., INC. (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041726-A1 | OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAINING | NAPEPLD, CNR2, PRKCE | LMNA 2580/4885PTGS1 1525/4885TRPA1 1996/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | LMNA 293/4885PTGS1 205/4885TRPA1 365/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | LMNA 3179/4885PTGS1 1738/4885TRPA1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.